

50. Meyer MC, Straughn AB. Biopharmaceutical factors in seizure control and drug toxicity. *Am J Hosp Pharm* 1993; 50 Suppl.: S17-22
51. Wolf P, May T, Tiska G, et al. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after slow release formulations. *Drug Res* 1992; 42: 284-8
52. Reunanen M, Heinonen EH, Nyman L, et al. Comparative bioavailability of carbamazepine from two slow-release preparations. *Epilepsy Res* 1992; 11: 61-6
53. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. *Clin Pharmacokinet* 1992; 22: 11-21
54. Patsalos PN. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. *Br J Clin Pharmacol* 1990; 29: 574-7
55. Cornaggia C, Gianetti S, Battino D, et al. Comparative pharmacokinetic study of chewable and conventional carbamazepine in children. *Epilepsia* 1993; 34: 158-60
56. Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous administration. *Br J Clin Pharmacol* 1978; 5: 313-8
57. Klotz U, Antonin KH. Pharmacokinetics and bioavailability of sodium valproate. *Clin Pharmacol Ther* 1977; 21: 736-43
58. Macdonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. *Neurology* 1987; 37: 1885
59. Trimble MR. Generic prescribing. *Hum Psychopharmacol* 1987; 2: 1-2
60. Biemann P, Levac T, Langlois Y, et al. Bioavailability of primidone in epileptic patients. *Int J Clin Pharmacol* 1974; 9: 132-7
61. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. *JAMA* 1987; 258: 1216-7
62. Cloyd JC, Leppik IE. Primidone: absorption, distribution, excretion. In: Levy RH, Mattson RH, Meldrum BS, editors. *Antiepileptic drugs*. 4th ed. New York: Raven Press, 1995: 459-66
63. Cramer JA, Mattson RH. Compliance with antiepileptic drug therapy. In: Levy RH, Mattson RH, Meldrum BS, editors. *Antiepileptic drugs*. 4th ed. New York: Raven Press, 1995: 149-59
64. Leppik IE, Cloyd JC, Sawchuk RJ, et al. Compliance and variability of plasma phenytoin levels in epileptic patients. *Ther Drug Monit* 1979; 1: 475-83
65. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. *JAMA* 1989; 261: 3273-7
66. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. *Neurology* 1990; 40: 1641-3
67. FDA policy on generic anticonvulsants. *Scrip* 1989; 1469: 28
68. Food and Drug Administration. FDA findings on generic drugs. *FDA Drug Bull* 1990; 20: 4-5

Correspondence and reprints: Prof. *Alan Richens*, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XN, Wales.

Erratum

Vol.7, No. 2, page 102: section 3.2. Sentence 1 of paragraph 3 should read 'Oral therapy with extended phenytoin sodium may be initiated at 300mg at bedtime.'

[Cheshire WP. *Trigeminal Neuralgia: A Guide to Drug Choice. CNS Drugs* 1997 Feb; 7 (2): 98-110]